Licensing agreements between pharmaceutical companies and the Medicines Patent Pool, in cooperation with the WHO, could accelerate access to doses for the poorest countries.
Can companies legally require workers to get vaccinated? Employers have gotten so good at finding ways to get employees to comply with their policies that it may not matter.
The amount of risk from overseas arrivals depends not just on Australia’s vaccination rates, but also on the particular circumstances of the country from which people are travelling.
Jamaal Abdul-Alim, The Conversation and Alvin Buyinza, The Conversation
As more people get vaccinated and different facets of society slowly reopen, challenges remain in the nation’s quest to get back to normal. Here are five articles that help illuminate the path.
Variants of the original SARS-CoV-2 are now in wide circulation. That means the third wave of COVID-19 has come with new questions about the variants, their effects and what might come next.
The fight for vaccine equity needs to stop looking to multilateral institutions for permission and instead focus on the policy tools that are already available to states.
If one adenoviral vaccine is linked with blood clots, it doesn’t mean all vaccines in this family will have that same effect. But it’s definitely worth health authorities assessing the data.
The one-dose vaccine developed by Johnson & Johnson is temporarily halted because of potentially serious blood clots seen in six women. An immunologist explains what this means for you.
Paediatrician at the Royal Childrens Hospital and Associate Professor and Clinician Scientist, University of Melbourne and MCRI, Murdoch Children's Research Institute